4.5 Article

Immunomodulatory molecules of Fasciola hepatica: Candidates for both vaccine and immunotherapeutic development

期刊

VETERINARY PARASITOLOGY
卷 195, 期 3-4, 页码 272-285

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.vetpar.2013.04.008

关键词

Fasciola hepatica; Immunotherapeutics; Immunomodulation; Secretory proteins; Cathepsin L; Peroxiredoxin; Helminth defence molecules

资金

  1. Canadian Institute of Health Research (CIHR)
  2. National Science and Engineering Council (NSERC)
  3. Ministere de l'Enseignement Superieur, de la Recherche, de la Science et de la Technologie, Quebec
  4. i3 Institute postdoctoral fellowship
  5. Programme for Research in Third Level Institutions (PRTLI) Cycle 4
  6. European Regional Development Fund (ERDF), part of the European Union Structural Funds Programme
  7. COST Action [BM1007]

向作者/读者索取更多资源

The liver fluke, Fasciola hepatica, causes fascioliasis in domestic animals (sheep, cattle), a global disease that is also an important infection of humans. As soon as the parasite invades the gut wall its interaction with various host immune cells (e.g. dendritic cells, macrophages and mast cells) is complex. The parasite secretes a myriad of molecules that direct the immune response towards a favourable non-protective Th2-mediate/regulatory environment. These immunomodulatory molecules, such as cathepsin L peptidase (FhCL1), are under development as the first generation of fluke vaccines. However, this peptidase and other molecules, such as peroxiredoxin (FhPrx) and helminth defence molecule (FhHDM-1), exhibit various immunomodulatory properties that could be harnessed to help treat immune-related conditions in humans and animals. (C) 2013 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据